Nivolumab: Five-Year Survival for Melanoma, RCC, and NSCLC

​ Five-year overall survival results have now been revealed for nivolumab in advanced melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC). "We report, to our knowledge, the longest combined clinical follow-up for patients with multiple cancer types receiving any anti–PD-L1 drug," the researchers comment in their secondary analysis of data from the phase I CA209-003 trial and expansion cohorts. This trial was the first multidose trial of nivolumab, an immunotherapy drug t...
Continue reading

Nivolumab for Untreated Advanced Classic Hodgkin Lymphoma

Nivolumab (Opdivo®, Bristol-Myers Squibb), an anti–programmed cell death protein 1 (anti–PD-1) monoclonal antibody, has been previously approved by the FDA for the treatment of refractory classic Hodgkin lymphoma (cHL). Now, in the CheckMate 205 phase 2 clinical trial, nivolumab shows promise in newly diagnosed advanced-stage cHL. In addition to refractory cHL, nivolumab is approved for the treatment of advanced lung cancer, melanoma, advanced kidney cancer, head and neck squamous cell cancer, a...
Continue reading

Simple Method Could Monitor Treatment Efficacy in Lung Cancer

Nivolumab (Opdivo®, Bristol-Myers Squibb), a checkpoint inhibitor, can help the immune system combat cancer cells. However, each patient responds to this treatment differently and needs to be monitored accordingly to gauge how it is interacting with the body. Researchers at Osaka University have devised a simple method for testing the impact of nivolumab. By analyzing small samples of blood and lung fluid in non-small cell lung cancer (NSCLC) patients, the researchers were able to measure the am...
Continue reading

Nivolumab Approved for Third-Line Treatment of Metastatic Small Cell Lung Cancer

The FDA has granted accelerated approval to nivolumab (Opdivo®, Bristol-Myers Squibb Company) for use as a third-line treatment for patients with metastatic small cell lung cancer (SCLC) who have progressed after platinum-based chemotherapy and one other line of therapy. SCLC is an aggressive disease which typically remains undetected until the cancer is in an advanced stage. Extensive stage or stage IV SCLC is currently associated with 5-year survival rates of approximately 2%. This approval ma...
Continue reading

Nivolumab/Ipilimumab Approved for Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma

The combination of nivolumab and ipilimumab (Opdivo and Yervoy, respectively, Bristol-Myers Squibb Co.) has received approval as first-line treatment for intermediate and poor-risk advanced renal cell carcinoma (RCC). Approval was contingent on findings from the randomized, open-label phase III CheckMate 214 trial (NCT02231749), which included treatment-naive patients diagnosed with advanced or metastatic clear cell RCC. Of the 1,096 patients enrolled, 847 had intermediate- or poor-risk RCC. Obj...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.